Artiva Halts AlloNK After Two Patient Deaths, Cuts 94% of Staff, Pursues Strategic Alternatives
ARTV sits 38% above its 52-week low of $2.96.
Summary
Artiva is discontinuing its lead NK-cell therapy AlloNK after updated durability data and two patient deaths, cutting about 94% of its workforce, and evaluating a sale, merger, or liquidation with roughly $319.1 million in cash on hand.
Key Events · Product Development and Regulatory · ARTV
-
AlloNK Development Discontinued
Artiva is halting all further development of AlloNK (AB-101), including the planned Phase 3 pivotal trial, after longer-term follow-up showed response durability below the threshold management required.
-
Two Grade 5 Safety Events
One trial participant died of leukoencephalopathy assessed as likely fludarabine toxicity; a second died suddenly about two months after treatment, assessed by the investigator as unrelated to study treatment. The FDA asked Artiva to pause Phase 2a enrollment and dosing.
-
94% Workforce Reduction
The board approved the wind-down on October 22, 2026, including a cut of approximately 94% of the current employee base, expected to be completed in the first quarter of 2027 with most costs incurred in Q4 2026. Total costs cannot yet be reasonably estimated.
-
Strategic Alternatives Under Review
The board is evaluating options that may include a merger, business combination, asset sale or licensing, or dissolution and liquidation, with Leerink Partners engaged as financial advisor. No assurance any transaction will result.
Analysis · ARTV · Life Sciences
Artiva's entire thesis was AlloNK, and it is now dead. Longer-term follow-up showed response durability below the bar management required, and two Grade 5 events — a fatal leukoencephalopathy case assessed as likely fludarabine toxicity and a second death assessed as unrelated to treatment — prompted the FDA to pause Phase 2a enrollment and dosing. The planned Phase 3 pivotal trial will not start. What remains is roughly $319.1 million of cash against a company cutting about 94% of its workforce and hiring Leerink Partners to shop a merger, asset sale, or liquidation. That cash is the whole valuation now: the stock trades on the per-share liquidation value and the odds of a deal, not on any clinical catalyst. The company said it will not update on the process until the board approves a specific course of action or the review concludes.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 45.6% of the 241 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTV was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $301.2M. The 52-week trading range was $2.96 to $14.53. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.